A
Antidote.me
Transforming the way that sponsors and patients connect in order to accelerate medical research
About Antidote.me
Antidote Technologies, Inc. operates in the healthcare sector, focusing on bridging the gap between patients and clinical research. The company offers precision recruitment services to pharmaceutical sponsors, helping them fill clinical trials faster and more efficiently. This service addresses a critical issue in medical research, where over 80% of studies are delayed due to a lack of participants. By leveraging advanced algorithms and patient data, Antidote matches patients with relevant clinical trials, ensuring that both parties benefit. The business model is primarily B2B, targeting pharmaceutical companies and research organizations who pay for the recruitment services. Revenue is generated through service fees and potentially performance-based incentives. Antidote also serves patients by providing a platform where they can easily find and enroll in clinical trials that match their medical conditions. This dual approach not only accelerates medical research but also offers patients access to cutting-edge treatments. Keywords: clinical trials, patient recruitment, precision recruitment, medical research, pharmaceutical sponsors, healthcare technology, patient matching, research acceleration, B2B services, clinical trial enrollment.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2010
- Headquarters
- North Miami Beach, United States
- Employees
- 24
- Open positions
- None listed
- Dealroom signal
- 62.3/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Sustainable Development Goals, UKis Digital and technologies, Clinical Trials, Tech for Biotech and Pharma, uk is8 digital and technologies, uk is8 life sciences, AI Drug Discovery
- Business model
- Marketplace & ecommerce
Latest news
Press, funding announcements and product moves mentioning Antidote.me.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jun 2021 | $23M | $92M | Smedvig Capital · Merck Global Health Innovation Fund · LBO France · Octopus Ventures | — |
| EARLY VCOther financing | Sep 2017 | $11M | $44M | Octopus Ventures · Smedvig Capital · Merck & Co. | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Antidote.me is 53K monthly website visits, down 38.4% over the last three months. Antidote.me's team declined 7.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
Ignota LabsUsing cutting-edge AI algorithms to predict toxic endpoints, earlier in the drug discovery process |
London, United Kingdom | Operational | 22 | $7M | $28M |
BenevolentAIBenevolentAI is a leading, clinical-stage AI-enabled drug discovery company |
London, United Kingdom | Operational | |||
HumaProvides a digital health platform used for predictive care and research |
London, United Kingdom | Operational | |||
HealxAI-drug discovery accelerating treatments for rare diseases |
Cambridge, United Kingdom | Operational | |||
SynthaceEngineering biology for health, food, energy and manufacturing. |
London, United Kingdom | Operational | |||
iLoFAI and photonics platform for personalized drug discovery. |
London, United Kingdom | Operational | |||
BiorelateA platform for analyzing scientific trends and connections for drug discovery with AI |
Manchester, United Kingdom | Operational | |||
DeepMatterMedical research and development services |
Glasgow, United Kingdom | Operational |
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A3 investors entered at this stage
Octopus Ventures
Smedvig Capital
Merck & Co.
Series B and later2 investors entered at this stage
Merck Global Health Innovation Fund
LBO France
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Antidote.me on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Antidote.me’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








